1 thought on “How’s the FDA doing on stem cell clinics? New Poll”

  1. I think the question should be addressing the FDA’s approach on stem cells as a biotechnological product similar to a drug, and definitely treated as one in regulatory affairs, than the institution’s leniency with clinics profiting or conducting research with stem cells.

Comments are closed.